血清IL－6和CRP水平在肺癌中的临床意义  

Clinical significance of serum IL-6 and CRP level in lung cancer patients

作　　者：庞慧[1] 张恩娟[1] 聂芳芳[1] 

机构地区：[1]焦作市第二人民医院肿瘤内科2区,河南焦作454001

出　　处：《中国伤残医学》2015年第14期33-36,共4页Chinese Journal of Trauma and Disability Medicine

摘　　要：目的：探讨白细胞介素－6（Interleukin－6，IL－6）和急性期反应蛋白（Acute Phase Reactive Protein， CRP）在非小细胞肺癌的辅助诊断及化疗疗效评价等方面的临床意义。方法：采用酶联免疫吸附法（ ELISA）检测61例初治肺癌患者、20例健康体检者、24例肺癌患者化疗前后血清IL－6和CRP的水平。结果：肺癌组血清IL－6和CRP水平均明显高于健康体检组，差异有显著性（P＜0．01）；IL－6和CRP水平均与性别、组织学类型无关，化疗有效（CR＋PR）或疾病控制（CR＋PR＋SD）的肺癌患者血清IL－6和CRP水平有不同程度下降，差异有显著性（P＜0．05），化疗无效者（PD）IL－6和CRP水平升高或无明显变化。结论：肺癌患者常伴有血清IL－6和CRP升高，化疗后2种炎症因子的变化与治疗反应明显相关，可以帮助评估化疗疗效。Objective：To discuss the clinical significance of serum Interleukin-6（ IL-6）and Acute phase response protein （CRP） level in aid diagnosis of lung cancer and evaluating effect of chemotherapy.Methods：To measure serum level of IL-6 and CRP in lung cancer patients, healthy group, before and after chemotherapeutic patients by enzyme linked immunosorbent assay（ ELISA）.Results：The mean serum IL-6 and CRP level in patients with lung cancer was higher than in the healthy（P0.05）.The serum IL-6 and CRP level decreased in the patients of effective chemotherapy, increased or had no change in the patients of disease progress.Conclusion：Serum IL-6 and CRP levels may be supplementary diagnostic factors.The change of Serum IL-6 and CRP levels before and after chemotherapy may help to evaluate the effect of chemotherapy.

关 键 词：肺癌 白介素-6 急性期反应蛋白 化疗 疗效 

分 类 号：R734.2[医药卫生—肿瘤]